TPO-RAs were well-tolerated and effective drugs for ITP with acceptable toxicity, which have been soon recommended by specialists as second-line therapy for ITP and even as first-line treatment in some patients (31, 51, 52). This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.